0000919574-24-003898.txt : 20240703 0000919574-24-003898.hdr.sgml : 20240703 20240703140010 ACCESSION NUMBER: 0000919574-24-003898 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240701 FILED AS OF DATE: 20240703 DATE AS OF CHANGE: 20240703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BRADSHER NEAL C CENTRAL INDEX KEY: 0001278388 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12830 FILM NUMBER: 241099448 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lineage Cell Therapeutics, Inc. CENTRAL INDEX KEY: 0000876343 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943127919 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2173 SALK AVENUE STREET 2: SUITE 200 CITY: CARLSBAD STATE: CA ZIP: 92008 BUSINESS PHONE: 5105213390 MAIL ADDRESS: STREET 1: 2173 SALK AVENUE STREET 2: SUITE 200 CITY: CARLSBAD STATE: CA ZIP: 92008 FORMER COMPANY: FORMER CONFORMED NAME: BIOTIME INC DATE OF NAME CHANGE: 19930328 4 1 ownership.xml X0508 4 2024-07-01 0 0000876343 Lineage Cell Therapeutics, Inc. LCTX 0001278388 BRADSHER NEAL C C/O BROADWOOD CAPITAL INC. 142 WEST 57TH STREET, 11TH FLOOR NEW YORK NY 10019 1 0 1 0 0 OPTION TO PURCHASE COMMON SHARES 0.9541 2024-07-01 4 A 0 75000 0 A 2034-07-01 COMMON SHARES 75000 75000 D OPTION TO PURCHASE COMMON SHARES 1.41 2033-07-01 COMMON SHARES 50000 50000 D OPTION TO PURCHASE COMMON SHARES 1.57 2032-07-01 COMMON SHARES 50000 50000 D OPTION TO PURCHASE COMMON SHARES 2.86 2031-07-01 COMMON SHARES 50000 50000 D OPTION TO PURCHASE COMMON SHARES 0.8263 2030-07-01 COMMON SHARES 40000 40000 D OPTION TO PURCHASE COMMON SHARES 1.03 2029-06-30 COMMON SHARES 40000 40000 D These options will vest and become exercisable on July 1, 2025, provided, that Neal C. Bradsher (the "Reporting Person") remains a member of the board of directors of Lineage Cell Therapeutics, Inc. (the "Issuer") on that date. These options were granted to the Reporting Person by the Issuer on July 1, 2024 as director compensation pursuant to the Issuer's 2021 Equity Incentive Plan, as amended. These options are currently exercisable. Neal C. Bradsher, /s/ Neal C. Bradsher 2024-07-03